Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.
Follow ZVRA
Zevra Therapeutics, Inc. (ZVRA) EV/Sales
As of 16 October 2026, Zevra Therapeutics, Inc. (ZVRA) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from 0.0× (June 2020) to 19.2× (December 2024); the current reading is higher than 49% of that period. That is below the Biotechnology industry median of 9.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.8× | (78.32%) |
| FY2024 | 17.5× | 121.43% |
| FY2023 | 7.9× | (7.29%) |
| FY2022 | 8.5× | 64.53% |
| FY2021 | 5.2× | (36.63%) |
| FY2020 | 8.2× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.3× | 47.24% |
| Mar 2026 | 3.6× | (4.50%) |
| Dec 2025 | 3.8× | (25.77%) |
| Sep 2025 | 5.1× | (16.17%) |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CLYM Climb Bio, Inc. compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| CRMD CorMedix Inc compare | 1.0× |
| WVE WAVE Life Sciences Ltd. compare | 2.2× |
| PHAT Phathom Pharmaceuticals, Inc. compare | 2.4× |
| ZVRA Zevra Therapeutics, Inc. | 3.4× |
| SLDB Solid Biosciences Inc. compare | 37.0× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 403× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)